10 Unusual Stocks Attracting Huge Interest In The Pre-Market Right Now


Here’s where we see the heat today:

Today we have huge movers in the tech space thanks to Oracle and RIM earnings, plus a drug breakthrough for Alkermes, JNJ’s latest take-out target, and more…

M&A: Johnson & Johnson (JNJ) us buying flu shot maker Crucell (CRXL), stock exploding

Read about the deal here.

FROM UGLY TO HORRID: Arena gets a negative vote from the FDA on its key treatment, stock collapsing, even after having already done so

THANKS FORBES: Orexigen (OREX) now diving after yesterday's massive rally

PHARMA CATALYST: Alkermes (ALKS) gets an OK from the FDA on Vivitrol, stock rising

KEY EARNINGS: Oracle (ORCL) is popping after beating expectations yesterday evening

See a transcript of their earnings call here.

KEY EARNINGS: Research In Motion (RIMM) pulled an 'Oracle', beating expectations atferhours and surging

See a breakdown of the earnings here. Also watch RIM's CEO go on an epic rant about how the Blackberry will beat back Apple & Android here.

OIL SPILL: BP (BP) completes their relief well... still waiting for the real relief rally

Read about the completion here.

M&A: The M&A saga around Casey's convenience stores continues... stock has lost some ground

Casey's is trying to push for a higher bid from its potential acquirer. Read about it here.

ODD: FSI International (FSII) rebounding hard on decent volume

Might it be due to increased analyst coverage? Not sure, read about it here.

ODD: Acorn Energy (ACFN) is falling quite a bit in the pre-market

SHORT TARGET: Chinese travel company UTA is stabilizing after being slammed by fraud allegations from Bronte Capital

We noticed some huge buying yesterday, but let us stress that we have no view on the stock, either positive or negative.

PHARMA CATALYST: Vivus (VVUS) is falling quite a bit, it might have something to do with bad news from the FDA

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.